English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Ceftazidime-avibactam is a novel β-lactam/β-lactamase inhibitor with activity against carbapenem-resistantEnterobacteriaceae (CRE) that produceKlebsiella pneumoniae carbapenemase (KPC). We report the first cases of ceftazidime-avibactam resistance to develop during treatment of CRE infections and identify resistance mechanisms. Ceftazidime-avibactam-resistantK. pneumoniae emerged in three patients after ceftazidime-avibactam treatment for 10 to 19 days. Whole-genome sequencing (WGS) of longitudinal ceftazidime-avibactam-susceptible and -resistantK. pneumoniae isolates was used to identify potential resistance mechanisms. WGS identified mutations in plasmid-bornebla KPC-3 , which were not present in baseline isolates.bla KPC-3 mutations emerged independently in isolates of a novel sequence type 258 sublineage and resulted in variant KPC-3 enzymes. The mutations were validated as resistance determinants by measuring MICs of ceftazidime-avibactam and other agents following targeted gene disruption inK. pneumoniae , plasmid transfer, andbla KPC cloning into competentEscherichia coli . In rank order, the impact of KPC-3 variants on ceftazidime-avibactam MICs was as follows: D179Y/T243M double substitution &gt; D179Y &gt; V240G. Remarkably, mutations reduced meropenem MICs ≥4-fold from baseline, restoring susceptibility inK. pneumoniae from two patients. Cefepime and ceftriaxone MICs were also reduced ≥4-fold against D179Y/T243M and D179Y variant isolates, but susceptibility was not restored. Reverse transcription-PCR revealed that expression ofbla KPC-3 encoding D179Y/T243M and D179Y variants was diminished compared tobla KPC-3 expression in baseline isolates. In conclusion, the development of resistance-conferringbla KPC-3 mutations inK. pneumoniae within 10 to 19 days of ceftazidime-avibactam exposure is troubling, but clinical impact may be ameliorated if carbapenem susceptibility is restored in certain isolates.

antimicrobial agents and chemotherapy

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne <i>bla</i> <sub>KPC-3</sub> Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla _KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections